Heart failure prevention with sodium-glucose cotransporter 2 inhibitors.
作者信息
Khan Muhammad Shahzeb, Butler Javed
机构信息
Department of Internal Medicine, John H Stroger Jr Hospital of Cook County, Chicago, IL.
Department of Medicine, University of Mississippi Medical Center, Jackson, MS.
出版信息
J Diabetes. 2019 Jul;11(7):601-604. doi: 10.1111/1753-0407.12932. Epub 2019 May 1.
Abstract
摘要
相似文献
1
Heart failure prevention with sodium-glucose cotransporter 2 inhibitors.
J Diabetes. 2019 Jul;11(7):601-604. doi: 10.1111/1753-0407.12932. Epub 2019 May 1.
2
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
Circulation. 2019 Nov 5;140(19):1569-1577. doi: 10.1161/CIRCULATIONAHA.119.042685. Epub 2019 Aug 31.
3
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Adv Ther. 2022 Feb;39(2):845-861. doi: 10.1007/s12325-021-01989-z. Epub 2021 Dec 9.
4
Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients.
J Diabetes Investig. 2021 Jan;12(1):6-20. doi: 10.1111/jdi.13329. Epub 2020 Aug 5.
5
Sodium-glucose co-transporter 2 inhibitors for the prevention of heart failure in type 2 diabetes: A systematic review and meta-analysis.
Eur J Prev Cardiol. 2020 Apr;27(6):667-670. doi: 10.1177/2047487319841936. Epub 2019 Apr 9.
6
Could Flozins Be the Statins for Risk-Based Primary Prevention of Heart Failure?
JAMA Cardiol. 2021 Jul 1;6(7):741-742. doi: 10.1001/jamacardio.2021.1133.
7
Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature.
Heart Fail Rev. 2024 Mar;29(2):549-558. doi: 10.1007/s10741-024-10388-9. Epub 2024 Feb 1.
8
Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.
Am J Cardiol. 2019 Dec 15;124 Suppl 1:S20-S27. doi: 10.1016/j.amjcard.2019.10.026.
9
Expanding the possibilities of using sodium-glucose cotransporter 2 inhibitors in patients with heart failure.
Wiad Lek. 2024;77(3):585-590. doi: 10.36740/WLek202403130.
10
Treatment with sodium-glucose cotransporter-2 inhibitors in heart failure patients: The potential benefits of monitoring FGF-23 levels?
Ann Endocrinol (Paris). 2022 Feb;83(1):78-80. doi: 10.1016/j.ando.2021.10.003. Epub 2021 Oct 30.
引用本文的文献
1
Sodium-Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes.
Card Fail Rev. 2019 Nov 4;5(3):169-172. doi: 10.15420/cfr.2019.06.R1. eCollection 2019 Nov.
本文引用的文献
1
Response by Figtree et al to Letter Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)".
Circulation. 2019 Jan 15;139(3):418-419. doi: 10.1161/CIRCULATIONAHA.118.038477.
2
Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
JACC Heart Fail. 2018 Oct;6(10):823-830. doi: 10.1016/j.jchf.2018.05.021. Epub 2018 Sep 5.
3
SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.
J Am Coll Cardiol. 2018 Jun 5;71(22):2497-2506. doi: 10.1016/j.jacc.2018.01.085.
4
Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.
J Am Coll Cardiol. 2018 Mar 27;71(12):1379-1390. doi: 10.1016/j.jacc.2018.01.047. Epub 2018 Mar 10.
5
The diabetic heart utilizes ketone bodies as an energy source.
Metabolism. 2017 Dec;77:65-72. doi: 10.1016/j.metabol.2017.08.005. Epub 2017 Aug 31.
6
CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection-and Maybe More.
Cell Metab. 2017 Nov 7;26(5):703-705. doi: 10.1016/j.cmet.2017.09.022. Epub 2017 Oct 19.
7
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
Diabetes Obes Metab. 2018 Mar;20(3):479-487. doi: 10.1111/dom.13126. Epub 2017 Nov 15.
8
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
Eur Heart J. 2018 Feb 1;39(5):363-370. doi: 10.1093/eurheartj/ehx511.
9
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.
10
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.
Zotero 插件